TY - JOUR T1 - Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals JF - medRxiv DO - 10.1101/2021.10.14.21265030 SP - 2021.10.14.21265030 AU - Chandima Jeewandara AU - Inoka Sepali Aberathna AU - Pradeep Darshana Pushpakumara AU - Achala Kamaladasa AU - Dinuka Guruge AU - Ayesha Wijesinghe AU - Banuri Gunasekera AU - Shyrar Tanussiya AU - Heshan Kuruppu AU - Thushali Ranasinghe AU - Shashika Dayarathne AU - Osanda Dissanayake AU - Nayanathara Gamalath AU - Dinithi Ekanayake AU - Jeewantha Jayamali AU - Deshni Jayathilaka AU - Madushika Dissanayake AU - Tibutius Thanesh Jayadas AU - Anushika Mudunkotuwa AU - Gayasha Somathilake AU - Michael Harvie AU - Thashmi Nimasha AU - Saubhagya Danasekara AU - Ruwan Wijayamuni AU - Lisa Schimanski AU - Pramila Rijal AU - Tiong K. Tan AU - Tao Dong AU - Alain Townsend AU - Graham S. Ogg AU - Gathsaurie Neelika Malavige Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/18/2021.10.14.21265030.abstract N2 - Background To determine the kinetics and persistence of immune responses following the Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan individuals.Methods SARS-CoV-2 specific total antibodies were measured in 20-to-39 year (n=61), 40-to-59-year and those >60 years of age (n=22) by ELISA, 12 weeks after the second dose of the vaccine. ACE2 receptor blocking antibodies (ACE2R-Ab), antibodies to the receptor binding domain (RBD) of the ancestral virus (WT) and variants of concern, were measured in a sub cohort. T cell responses and memory B cell responses were assessed by ELISpot assays.Results 193/203 (95.07%) of individuals had detectable SARS-CoV-2 specific total antibodies, while 67/110 (60.9%) had ACE2R-Ab. 14.3% to 16.7% individuals in the 20 to 39 age groups had detectable antibodies to the RBD of the WT and VOC, while the positivity rates of those >60 years of age was <10%. 14/49 (28.6%) had IFNγ ELISpot responses to overlapping peptides of the spike protein, while memory B cell responses were detected in 9/20 to the S1 recombinant protein. The total antibody levels and ACE2R-Ab declined after 2 to 12 weeks from the second dose, while ex vivo T cell responses remained unchanged. The decline in ACE2R-Ab levels was significant among the 40 to 59 (p=0.0007) and ≥60 (p=0.005) age groups.Conclusions Antibody responses declined in all age groups, especially in those >60 years, while T cell responses persisted. The effect of waning of immunity on hospitalization and severe disease should be assessed by long term efficacy studies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is not a clinical trial.Funding StatementWe are grateful to the Allergy, Immunology and Cell Biology Unit, University of Sri Jayewardenepura; the NIH, USA (grant number 5U01AI151788-02), UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Ethics Review Committee of University of Sri Jayewardenepura.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. ER -